Premium
Application of Prescription Drug Monitoring Program to detect underreported controlled substance use in patients evaluated for liver transplant
Author(s) -
Halpern Samantha J.,
Walls David O.,
Gupta Anuranita,
Lustig Alexa,
Weinrieb Robert,
Levine Matthew H.,
Abt Peter L.
Publication year - 2019
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.15548
Subject(s) - medicine , medical prescription , drug , referral , retrospective cohort study , substance use , controlled substance , liver transplantation , cohort , emergency medicine , intensive care medicine , pharmacology , family medicine , transplantation , psychiatry
Presurgical controlled substance use predicts postoperative complications, increased readmissions, and mortality. We aimed to examine if a Prescription Drug Monitoring Program ( PDMP ) would detect underreported controlled substance use in patients undergoing liver transplant evaluation. We performed a retrospective cohort study at a tertiary referral center of patients undergoing liver transplant evaluation in 2017. PDMP reviews were performed on all 360 patients and urine drug screen ( UDS ) results were reviewed when available to evaluate dispensed controlled substances. These results were compared to the patient's self‐reported medication list at evaluation to identify any underreporting. The primary outcome was the number of self‐reported controlled substance discrepancies on the medication list identified by PDMP and UDS at the time of evaluation. Among the 360 patients, 87 (24%) had a discrepancy where PDMP revealed a controlled substance prescription that the patient did not report on their medication list. Seventy‐seven (67/87) of these discrepancies involved opiates. Of the 360 patients, 219 (61%) had a negative UDS , but 70 (32%) of these patients had at least one controlled substance listed on PDMP . PDMP is a promising screening tool when used in conjunction with the UDS for detecting underreported controlled substance use in liver transplant candidates.